Josie Hayes1, Helene Thygesen2, Walter Gregory3, David R Westhead4, Pim J French5, Martin J Van Den Bent6, Sean E Lawler7, Susan C Short8. 1. Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds LS9 7TF, UK. Electronic address: Josielouise.hayes@ucsf.edu. 2. Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. 3. Clinical Trials Research Unit (CTRU), University of Leeds, 71-75 Clarendon Road, Leeds, West Yorkshire LS2 9JT, UK. 4. Institute of Molecular and Cellular Biology, Faculty of Biological Sciences and Institute of Membrane and Systems Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK. 5. Department of Neurology, Brain Tumor Center, Erasmus MC Cancer Institute, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands. 6. Department of Neurology, Brain Tumor Center, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands. 7. Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. 8. Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds LS9 7TF, UK.
Abstract
PURPOSE: We investigated whether microRNA expression data from glioblastoma could be used to produce a profile that defines a bevacizumab responsive group of patients. PATIENTS AND METHODS: TCGA microRNA expression data from tumors resected at first diagnosis of glioblastoma in patients treated with bevacizumab at any time during the course of their disease were randomly separated into training (n = 50) and test (n = 37) groups for model generation. MicroRNA-seq data for 51 patients whose treatment included bevacizumab in the BELOB trial were used as an independent validation cohort. RESULTS: Using penalized regression we identified 8 microRNAs as potential predictors of overall survival in the training set. We dichotomized the response score based on the most prognostic minimum of a density plot of the response scores (log-rank HR = 0.16, p = 1.2e(-5)) and validated the profile in the test cohort (one-sided log-rank HR = 0.34, p = 0.026). Analysis of the profile using all samples in the TCGA glioblastoma dataset, regardless of treatment received, (n = 473) showed that the prediction of patient benefit was not significant (HR = 0.84, p = 0.083) suggesting the profile is specific to bevacizumab. Further independent validation of our microRNA profile in RNA-seq data from patients treated with bevacizumab (alone or in combination with CCNU) at glioblastoma recurrence in the BELOB trial confirmed that our microRNA profile predicted patient benefit from bevacizumab (HR = 0.59, p = 0.043). CONCLUSION: We have identified and validated an 8-microRNA profile that predicts overall survival in patients with glioblastoma treated with bevacizumab. This may be useful for identifying patients who are likely to benefit from this agent.
PURPOSE: We investigated whether microRNA expression data from glioblastoma could be used to produce a profile that defines a bevacizumab responsive group of patients. PATIENTS AND METHODS: TCGA microRNA expression data from tumors resected at first diagnosis of glioblastoma in patients treated with bevacizumab at any time during the course of their disease were randomly separated into training (n = 50) and test (n = 37) groups for model generation. MicroRNA-seq data for 51 patients whose treatment included bevacizumab in the BELOB trial were used as an independent validation cohort. RESULTS: Using penalized regression we identified 8 microRNAs as potential predictors of overall survival in the training set. We dichotomized the response score based on the most prognostic minimum of a density plot of the response scores (log-rank HR = 0.16, p = 1.2e(-5)) and validated the profile in the test cohort (one-sided log-rank HR = 0.34, p = 0.026). Analysis of the profile using all samples in the TCGA glioblastoma dataset, regardless of treatment received, (n = 473) showed that the prediction of patient benefit was not significant (HR = 0.84, p = 0.083) suggesting the profile is specific to bevacizumab. Further independent validation of our microRNA profile in RNA-seq data from patients treated with bevacizumab (alone or in combination with CCNU) at glioblastoma recurrence in the BELOB trial confirmed that our microRNA profile predicted patient benefit from bevacizumab (HR = 0.59, p = 0.043). CONCLUSION: We have identified and validated an 8-microRNA profile that predicts overall survival in patients with glioblastoma treated with bevacizumab. This may be useful for identifying patients who are likely to benefit from this agent.
Authors: Josie Hayes; Helene Thygesen; Walter Gregory; David R Westhead; Pim J French; Martin J Van Den Bent; Sean E Lawler; Susan C Short Journal: Mol Oncol Date: 2016-07-01 Impact factor: 6.603
Authors: Thomas Sandmann; Richard Bourgon; Josep Garcia; Congfen Li; Timothy Cloughesy; Olivier L Chinot; Wolfgang Wick; Ryo Nishikawa; Warren Mason; Roger Henriksson; Frank Saran; Albert Lai; Nicola Moore; Samir Kharbanda; Franklin Peale; Priti Hegde; Lauren E Abrey; Heidi S Phillips; Carlos Bais Journal: J Clin Oncol Date: 2015-06-29 Impact factor: 44.544
Authors: Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: Benjamin P Lewis; I-hung Shih; Matthew W Jones-Rhoades; David P Bartel; Christopher B Burge Journal: Cell Date: 2003-12-26 Impact factor: 41.582
Authors: L A M Gravendeel; J J de Rooi; P H C Eilers; M J van den Bent; P A E Sillevis Smitt; P J French Journal: Br J Cancer Date: 2011-12-20 Impact factor: 7.640
Authors: Ana Costa; Joana Afonso; Catarina Osório; Ana L Gomes; Francisco Caiado; Joana Valente; Sandra I Aguiar; Francisco Pinto; Mário Ramirez; Sérgio Dias Journal: J Hematol Oncol Date: 2013-11-21 Impact factor: 17.388
Authors: J Saadi Imam; Jason R Plyler; Hima Bansal; Suresh Prajapati; Sanjay Bansal; Jennifer Rebeles; Hung-I Harry Chen; Yao-Fu Chang; Subbarayalu Panneerdoss; Behyar Zoghi; Kalyan C Buddavarapu; Russell Broaddus; Peter Hornsby; Gail Tomlinson; Jeffrey Dome; Ratna K Vadlamudi; Alexander Pertsemlidis; Yidong Chen; Manjeet K Rao Journal: PLoS One Date: 2012-12-21 Impact factor: 3.240
Authors: Josie Hayes; Helene Thygesen; Walter Gregory; David R Westhead; Pim J French; Martin J Van Den Bent; Sean E Lawler; Susan C Short Journal: Mol Oncol Date: 2016-07-01 Impact factor: 6.603
Authors: Arun K Rooj; Franz Ricklefs; Marco Mineo; Ichiro Nakano; E Antonio Chiocca; Agnieszka Bronisz; Jakub Godlewski Journal: Cell Rep Date: 2017-06-06 Impact factor: 9.423
Authors: Jennifer Jeck; Rebecca Kassubek; Jan Coburger; Simone Edenhofer; Stefan S Schönsteiner; Albert C Ludolph; Bernd Schmitz; Jens Engelke; Regine Mayer-Steinacker; Jan Lewerenz; Lars Bullinger Journal: Ther Adv Neurol Disord Date: 2018-01-21 Impact factor: 6.570
Authors: Kerstin A Kessel; Josefine Hesse; Christoph Straube; Claus Zimmer; Friederike Schmidt-Graf; Jürgen Schlegel; Bernhard Meyer; Stephanie E Combs Journal: PLoS One Date: 2017-07-05 Impact factor: 3.240